RadNet acquires Aidence and Quantib, outlines AI strategy for cancer screening and operations

RadNet, Inc.

Acquired Aidence (AI for lung cancer screening) and Quantib (AI for prostate MRI) to bolster AI portfolio.
Conference call highlighted AI opportunities in clinical enhancements, business ops, and revenue growth.
Dr. Greg Sorensen, CEO of DeepHealth, leads RadNet's AI division.
Financial terms of the acquisitions were not disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.